ABSTRACT
Background Little is known regarding the long-term adverse effects of COVID-19 on female-specific cancers due to the restricted length of observational time, nor the shared genetic influences underlying these conditions.
Methods Leveraging summary statistics from the hitherto largest genome-wide association studies conducted in each trait, we performed a comprehensive genome-wide cross-trait analysis to investigate the shared genetic architecture and the putative genetic associations between COVID-19 with three main female-specific cancers: breast cancer (BC), epithelial ovarian cancer (EOC), and endometrial cancer (EC). Three phenotypes were selected to represent COVID-19 susceptibility (SARS-CoV-2 infection) and severity (COVID-19 hospitalization, COVID-19 critical illness).
Results For COVID-19 susceptibility, we found no evidence of a genetic correlation with any of the female-specific cancers. For COVID-19 severity, we identified a significant genome-wide genetic correlation with EC for both hospitalization (rg=0.19, P=0.01) and critical illness (rg =0.29, P=3.00×10−4). Mendelian randomization demonstrated no valid association of COVID-19 with any cancer of interest, except for suggestive associations of genetically predicted hospitalization (ORIVW=1.09, 95%CI=1.01-1.18, P=0.04) and critical illness (ORIVW=1.06, 95%CI=1.00-1.11, P=0.04) with EC risk, none withstanding multiple correction. No reverse association was found. Cross-trait meta-analysis identified multiple pleiotropic SNPs between COVID-19 and female-specific cancers, including 20 for BC, 15 for EOC, and 5 for EC. Transcriptome-wide association studies revealed shared genes, mostly enriched in the hematologic, cardiovascular, and nervous systems.
Conclusions Our genetic analysis highlights an intrinsic link underlying female-specific cancers and COVID-19 - while COVID-19 is not likely to elevate the immediate risk of the examined female-specific cancers, it appears to share mechanistic pathways with these conditions. These findings may provide implications for future therapeutic strategies and public health actions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by funds from the National Natural Science Foundation of China (81874283, 81673255, 81874282), the National Key R&D Program of China (2020YFC2006505), the Health Commission of Sichuan Province (20PJ093), the Key R&D Program of Sichuan, China (2022YFS0055), the Recruitment Program for Young Professionals of China, the Promotion Plan for Basic Medical Sciences, the Development Plan for Cutting-Edge Disciplines, Sichuan University, and other Projects from West China School of Public Health and West China Fourth Hospital, Sichuan University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study did not generate new datasets. All data used in our study are publicly-available. GWAS summary statistics of the COVID-19 Host Genetics Initiative are accessible at https://www.covid19hg.org/. GWAS summary statistics for breast cancer, epithelial ovarian cancer, and endometrial cancer can be downloaded from the GWAS catalog (https://www.ebi.ac.uk/gwas/) or from the websites of the consortium (http://bcac.ccge.medschl.cam.ac.uk/bcacdata/, http://ocac.ccge.medschl.cam.ac.uk/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study did not generate new datasets or codes. All data used in our study are publicly-available. GWAS summary statistics of the COVID-19 Host Genetics Initiative are accessible at https://www.covid19hg.org/. GWAS summary statistics for breast cancer, epithelial ovarian cancer, and endometrial cancer can be downloaded from the GWAS catalog (https://www.ebi.ac.uk/gwas/) or from the websites of the consortium (http://bcac.ccge.medschl.cam.ac.uk/bcacdata/, http://ocac.ccge.medschl.cam.ac.uk/). More details of the approaches as well as the codes are available at https://github.com/bulik/ldsc (LDSC), https://mrcieu.github.io/TwoSampleMR/ (TwoSampleMR), http://hal.case.edu/~xxz10/zhuweb/ (CPASSOC), https://github.com/hailianghuang/FM-summary (FM-summary), https://chr1swallace.github.io/coloc/ (Coloc), https://www.cog-genomics.org/plink/1.9/ (PLINK), https://grch37.ensembl.org/info/docs/tools/vep/index.html (VEP), http://gusevlab.org/projects/fusion/ (FUSION).
